-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Missfresh, Molecular Partners, TG Therapeutics, and 17EdTech and Encourages Investors to Contact the Fi
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating TG Therapeutics, Allianz, Outset Medical, and TrueBlue and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating Clariant, TG Therapeutics, Coinbase, and GoodRx and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
-
-
-
-
-
-
-
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
-
-
-
-
-
-
-
TG Therapeutics (TGTX) Announces FDA Acceptance of NDA for Umbralisib as Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
-
-
15,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

